Histogen Announces Second Adjournment of Special Meeting of Stockholders
14 déc. 2023 16h15 HE
|
Histogen Inc
Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023...
Histogen Announces Adjournment of Special Meeting of Stockholders
05 déc. 2023 16h05 HE
|
Histogen Inc
SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO) today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, December 14,...
Histogen Announces Board Approval of Complete Liquidation and Dissolution
18 sept. 2023 16h05 HE
|
Histogen Inc
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has...
Histogen to Explore Strategic Alternatives
05 juil. 2023 16h05 HE
|
Histogen Inc
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small...
Histogen Reports First Quarter 2023 Results and Provides Business Update
11 mai 2023 16h05 HE
|
Histogen Inc
Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emricasan Treatment has Therapeutic Effect Against...
Histogen Announces Online Publication in the Journal of Investigative Dermatology
20 avr. 2023 16h15 HE
|
Histogen Inc
Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases ...
Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University
03 avr. 2023 16h05 HE
|
Histogen Inc
Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases ...
Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use
16 mars 2023 16h05 HE
|
Histogen Inc
The Newly Issued Patent is Expected to Provide Protection into 2040 Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, March 16, 2023...
Histogen Reports Year-End 2022 Results and Provides Business Update
09 mars 2023 16h05 HE
|
Histogen Inc
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule...
Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
27 févr. 2023 16h15 HE
|
Histogen Inc
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments...